CARBOPLATINE MEDAC 10 mg/mL
Sponsors
Institut Jules Bordet, Institut Curie, Gilead Sciences Inc., Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Institut Gustave Roussy
Conditions
Advanced stage NSCLCBreast cancerFIGO stage III ovarian cancer who are eligible for primary cytoreductive surgery resulting in non-residual diseaseLocally Advanced/Metastatic Urothelial CancerLung CancerNSCLCPatients with High Risk NeuroblastomaThe patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.
Phase 1
"FAP-IT"
68Ga-FAPI-46 PET/CT for predicting histological response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer
RecruitingCTIS2023-507860-37-00
Start: 2024-10-14Target: 300Updated: 2025-11-10
Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
RecruitingCTIS2024-515087-31-00
Start: 2024-09-10Target: 260Updated: 2025-12-17
Phase 2
Immunological variables associated to ICI toxicity in cancer patients
RecruitingCTIS2023-505360-11-00
Start: 2022-08-18Target: 441Updated: 2025-04-22
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
RecruitingCTIS2023-508302-24-00
Start: 2019-05-07Target: 116Updated: 2025-10-22
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR
mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
CompletedCTIS2024-516201-23-00
Start: 2019-08-26End: 2025-04-09Target: 150Updated: 2024-11-05
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08
Not yet recruitingCTIS2024-516077-72-02
Target: 50Updated: 2024-11-28
Phase 3
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy:
OVHIPEC-2
Active, not recruitingCTIS2023-509049-11-00
Start: 2020-01-01Target: 485Updated: 2025-07-30
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN)
CompletedCTIS2024-516581-11-00
End: 2025-01-17Target: 84Updated: 2024-11-08
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) “Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
RecruitingCTIS2024-514917-36-00
Start: 2024-11-21Target: 719Updated: 2025-01-17